A 2026 Danish study found that starting a statin within one year of a type 2 diabetes diagnosis was associated with a lower risk of dementia. It did not prove that statins—medicines used to lower cholesterol and cardiovascular risk—prevent dementia. The association was strongest among early starters, but the absolute difference was modest. The findings can inform a conversation about statin timing, not replace an individual cardiovascular-risk assessment.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the researchers study?
- How large was the difference?
- Does this mean statins prevent dementia?
- What should someone with diabetes do now?
What did the researchers study?
This was a nationwide observational study, not a randomized dementia-prevention trial. Researchers followed 132,585 statin-naïve people—those not already taking statins—who developed type 2 diabetes in Denmark from 2006 through 2019. The study tracked all-cause dementia through December 31, 2021. It compared three groups: people who started statins within one year, those who started one to five years later, and those who did not start within five years.
These methods are detailed in The Lancet Regional Health–Europe study. Median follow-up was 7.1 years. During that period, 3,592 participants, or 2.7%, developed dementia. The researchers treated death as a competing risk when estimating 10-year outcomes.
How large was the difference?
People who started a statin within one year had an estimated 10-year dementia risk of 3.3%. The corresponding estimate was 3.9% among those who did not start within five years—an absolute difference of 0.59 percentage points, according to the published study. Relative-risk figures make the result appear larger. Compared with no initiation, early initiation was associated with a 15% lower relative risk of dementia.
The 95% confidence interval ranged from 9% to 21%. Starting one to five years after diagnosis was associated with a 10% lower relative risk. Its 95% confidence interval ranged from 3% to 15%. Both comparisons favored statin use, with the stronger association among early starters.
Does this mean statins prevent dementia?
No. An observational study can identify an association, but it cannot establish that the treatment caused the outcome. People who begin statins earlier may differ from nonusers in ways that influence dementia risk. The study's authors explicitly said randomized trial evidence is needed before concluding that statins prevent dementia.
A randomized trial would better separate the effect of statin treatment from other differences between the groups. The result also needs perspective. The early-treatment group's estimated risk was 0.59 percentage points lower over 10 years, despite a 15% relative reduction. Absolute risk shows the expected difference between groups more directly.
What should someone with diabetes do now?
Do not start, stop, or delay a statin solely because of this dementia study. Current statin decisions for people with diabetes remain based on cardiovascular prevention rather than a proven dementia benefit. The American Diabetes Association recommends moderate-intensity statin therapy for most adults ages 40 to 75 who have diabetes but no atherosclerotic cardiovascular disease, or ASCVD.
That guidance appears in the 2026 Standards of Care cardiovascular recommendations. At a clinical appointment, useful questions include: For someone already taking a statin, this observational finding is not a reason to change treatment independently. For someone newly diagnosed with type 2 diabetes, it supports discussing recommended cardiovascular prevention promptly while recognizing that dementia prevention remains unproven.
- Do I meet the current cardiovascular criteria for statin treatment?
- If I qualify, is there a reason to delay starting?
- What treatment intensity fits my cardiovascular risk?
- How should we review any concerns about taking the medicine?
You Might Also Like
- What Is New With Blog News for Dementia Care in August 2026? Latest FDA, NIH, WHO, and CMS sources and Key Takeaways
- The NIA 2026 Dementia Care and Caregiving Summit Report: What the Report Means for Family Caregivers
- The $781 Billion Dementia Economic Estimate in the 2026 NIA Report: What the Report Means for Family Caregivers
